Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Oak Therapeutics and Children’s Hospital Los Angeles to Collaborate on Novel MedicationBy: Oak Therapeutics Together, Oak and CHLA will develop and test a child-friendly formulation of a common anti-infective medication – one that is crucial for children being treated with chemotherapy and radiation therapy. These efforts will be led by Michael Neely, MD, Associate Professor of Pediatrics at the University of Southern California, member of the CHLA Division of Infectious Diseases, and Director of the Laboratory of Applied Pharmacokinetics and Bioinformatics at the Saban Research Institute at CHLA. The immune systems of children with cancer are often severely weakened by radiation and chemotherapy. To avoid secondary infections, which can be fatal, these children need to take preventive antibiotics four to six times a week for up to five years. Often, these antibiotics are extremely unpleasant tasting, adding to the burden of cancer treatment and resulting in a child’s refusal to take these essential medicines, according to Ashley Margol, MD, assistant professor in the Division of Hematology, Oncology and Blood & Marrow Transplantation at CHLA. Oak Therapeutics has developed a thin, stamp-sized film embedded with therapeutic levels of encapsulated medication, which easily dissolves in a child’s mouth, and which is flavored to mask the unpleasant taste of the medication. Under the agreement, CHLA and Oak Therapeutics will conduct a clinical investigation to test the reformulated antibiotic. The results of this investigation could support regulatory approval and attract investment to commercialize the product. The clinical investigation will be co-led by Drs. Neely and Margol. “This reformulated antibiotic, Anbactra™, is the first application of our technology for the benefit of pediatric patients,” said Ed Maliski, PhD, president and CEO of Oak Therapeutics, adding that the corporation is also developing other products using their proprietary formulation, including pediatric malaria medicines, antiretroviral medicines for pediatric HIV patients, and children’s oral rehydration supplements that can be used in the treatment of diarrhea, one of the planet’s deadliest ailments. “CHLA’s clinical and business expertise in developing medicines tailored to children, leveraged with Oak Therapeutics’ About Oak Therapeutics: Oak Therapeutics, Inc. is a privately held corporation that develops and applies medication delivery technologies for therapeutic agents with an emphasis on pediatric and prenatal products. To do this, Oak Therapeutics reformulates existing pharmaceuticals and nutraceuticals using a proprietary drug delivery system, oral dissolvable strips (ODS), and distributes them where they're needed most for children everywhere and especially in regions where people die from diseases that have known, simple cures. About Children’s Hospital Los Angeles: Children's Hospital Los Angeles has been named the best children’s hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children’s Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children’s Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. Contact and Further Information: Ed Maliski, Ph.D. Oak Therapeutics 1612 Fiske Pl Oxnard, CA 93033 Email: maliski@oaktherapeutics.com Phone: 805-907-5679 End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number